Skip to main content
Fig. 2 | BMC Rheumatology

Fig. 2

From: Effectiveness and safety of intravenous golimumab with and without concomitant methotrexate in patients with rheumatoid arthritis in the prospective, noninterventional AWARE study

Fig. 2

Proportion of all patients in remission (CDAI ≤ 2.8) and with low disease activity (CDAI > 2.8 to ≤ 10), moderate disease activity (CDAI > 10 to ≤ 22), and high disease activity (CDAI > 22) at baseline (a) and Months 3 (b), 6 (c), and 12 (d) for IV golimumab with and without methotrexate. CDAI Clinical Disease Activity Index, IV intravenous

Back to article page

BMC Rheumatology

ISSN: 2520-1026

Contact us